Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

0.4920 -0.0030 (-0.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bluebird Bio

< Previous 1 2 3 4 5 6 7 8 9 Next >
bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
From bluebird bio, Inc.
Via Business Wire
bluebird bio Inc. (NASDAQ: BLUE) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
bluebird bio Inc. (NASDAQ: BLUE) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc.
Via Business Wire
bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Host Third Quarter 2023 Financial Results Conference Call
From bluebird bio, Inc.
Via Business Wire
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
bluebird bio Announces September Investor Events
From bluebird bio, Inc.
Via Business Wire
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease
From bluebird bio, Inc.
Via Business Wire
bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events
From bluebird bio
Via Business Wire
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
From bluebird bio, Inc.
Via Business Wire
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
bluebird bio Sells Second Priority Review Voucher for $95 Million
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
From bluebird bio, Inc.
Via Business Wire
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
From bluebird bio, Inc.
Via Business Wire
FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18
From bluebird bio, Inc.
Via Business Wire
New Data from bluebird bio’s Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting
From bluebird bio inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.